Date: 2017-08-01
Type of information: Series B financing round
Company: Homology Medicines (USA - MA)
Investors: 5AM Ventures (USA - CA) Alexandria Venture Investments (USA - MA) ARCH Venture Partners (USA - IL) Deerfield Management (USA - NY) Fidelity Management and Research Company (US - MA) HBM Healthcare Investments (Switzerland) Maverick Ventures USA - CA) Novartis (Switzerland) Rock Springs Capital (USA - MD) Vida Ventures (Canada) Vivo Capital (USA - CA)
Amount: $83.5 million
Funding type: series B financing round
Planned used:
- The proceeds from the Series B are expected to be used to advance Homology’s lead development candidate that is currently in preclinical IND-enabling studies for an inborn error of metabolism disease. The proceeds are also expected to support continued work to progress Homology’s AMEnDR™ (AAV-Mediated Editing by Direct Homologous Recombination) technology into the clinic for rare genetic diseases with high unmet medical need. AMEnDR is a broadly applicable platform that enables highly efficient homologous recombination-based in vivo genomic correction of disease mutations or precise insertion of therapeutic sequences. Unlike other gene editing approaches, AMEnDR does not use exogenous nucleases or promoters. AMEnDR has demonstrated highly efficient on-target gene correction capabilities in multiple preclinical models.
Others:
- • On August 1, 2017, Homology Medicines, a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients, announced the closing of an $83.5 million Series B financing led by Deerfield Management. New investors include Fidelity Management and Research Company, HBM Healthcare Investments, Maverick Ventures, Novartis, Rock Springs Capital, Vida Ventures, Vivo Capital and Alexandria Venture Investments. Existing investors 5AM Ventures, ARCH Venture Partners and Temasek also participated in the financing.
- Homology has raised $127 million since the Company launched in 2016.
- In conjunction with the financing, Homology has appointed Cam Wheeler and Mahendra Shah, Ph.D., Managing Director at Vivo Capital, to its Board of Directors.
?
Therapeutic area: Rare diseases - Genetic diseases
Is general: Yes
